Rockefeller Capital Management
CBAY

Rockefeller Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Rockefeller Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$156K – 4073
2022
Q4 		$156K Sell
25,000
-189,200
-88% -$719K ﹤0.01% 1790
2022
Q3 		$749K Hold
214,200
– – ﹤0.01% 1117
2022
Q2 		$631K Sell
214,200
-13,175
-6% -$31.5K ﹤0.01% 1174
2022
Q1 		$707K Buy
227,375
+525
+0.2% +$1.65K ﹤0.01% 1186
2021
Q4 		$766K Buy
226,850
+102,850
+83% +$390K ﹤0.01% 1151
2021
Q3 		$452K Buy
124,000
+25,000
+25% +$98.5K ﹤0.01% 1302
2021
Q2 		$431K Buy
+99,000
New +$439K ﹤0.01% 1252

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rockefeller Capital Management's CBAY Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 25,000 shares — an estimated $156K sold.

Rockefeller Capital Management first reported a position in CBAY in Q2 2021 and held it in 7 quarters. The position peaked at $766K in Q4 2021. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 25,000 Cymabay Therapeutics shares in Q1 2023, an estimated $156K.
  • Rockefeller Capital Management first reported a position in Cymabay Therapeutics in Q2 2021 and held it in 7 quarters.
  • Rockefeller Capital Management's Cymabay Therapeutics position peaked at $766K in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.